PUBLICATIONS

PUBLICATIONS

  • 10

    Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis

    Clinical and Molecular Hepatology. 2024. Impact factor: 16.9

    Hee Yeon Kim, Jung Hwan Yu, Young Eun Chon, Seung Up Kim, Mi Na Kim, Ji Won Han, Han Ah Lee, Young Joo Jin, Ji Hyun An, Mi Young Choi, Dae Won Jun

    Link
  • 9

    KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease

    Clinical and Molecular Hepatology. 2024. Impact factor: 16.9

    Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young Joo Jin, Seung seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, Young Rok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL)

    Link
  • 8

    Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings

    Hepatology. 2024. Impact factor: 15.8

    Chul-Min Lee, Eileen L Yoon, Mimi Kim, Bo-Kyeong Kang, Seon Cho, Eun-Hee Nah, Dae Won Jun

    Link
  • 7

    A novel 11β-HSD1 inhibitor ameliorates liver fibrosis by inhibiting the notch signaling pathway and increasing NK cell population

    Arch Pharm Res. 2025. Impact factor: 7.5

    Ji Eun Kim, Yun Kim, Jiwon Bae, Eileen Laurel Yoon, Hyun Sung Kim, Sung Ryol Lee, Tae Hyun Yoon, Dae Won Jun

    Link
  • 6

    Is lifestyle modification effective for individuals with high fibrosis-4 index without an additional 2nd tier test?

    Hepatology. 2023. Impact factor: 15.8

    Huiyul Park, Eileen L Yoon, Mimi Kim, Sun-Hong Kwon, Dae Won Jun, Hye-Lin Kim

    Link
  • 5

    Biomarker-Driven Optimization of Saponin Therapy in MASLD: From Mouse Models to Human Liver Organoids

    Antioxidants. 2025. Impact factor: 6.6

     Hye Young Kim, Ju Hee Oh, Hyun Sung Kim, Dae Won Jun

    Link
  • 4

    Adenosine triphosphate-binding pocket inhibitor for mixed lineage kinase domain-like protein attenuated alcoholic liver disease via necroptosis-independent pathway

    World J Gastroenterol. 2025. Impact factor: 5.4

    Han-Ning Xuan Yuan, Hyun Sung Kim, Gye Ryeol Park, Jae Eun Ryu, Ji Eun Kim, In Young Kang, Hye Young Kim, Seung Min Lee, Ju Hee Oh, Eileen L Yoon, Dae Won Jun

    Link
  • 3

    Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease

    Nutrients. 2024. Impact factor: 5.0

    Eun Jeoung Lee, Seung Min Lee, Ju Hee Oh, Hye Young Kim, Waqar Khalid Saeed, Hyun Sung Kim, Dae Won Jun

    Link
  • 2

    Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study

    Clinical Gastroenterology and Hepatology. 2023. Impact factor: 12.6

    Angela Chau, Ming-Lun Yeh, Pei-Chien Tsai, Daniel Q Huang, Sung Eun Kim, Huy Trinh, Eileen L Yoon, Hyunwoo Oh, Jae Yoon Jeong, Sang Bong Ahn, Jihyun An, Cheng-Hao Tseng, Yao-Chun Hsu, Soung Won Jeong, Yong Kyun Cho, Jae-Jun Shim, Hyoung Su Kim, Takanori Ito, Sebastián Marciano, Keigo Kawashima, Takanori Suzuki, Tsunamasa Watanabe, Akito Nozaki, Toru Ishikawa, Kaori Inoue, Yuichiro Eguchi, Haruki Uojima, Hiroshi Abe, Hirokazu Takahashi, Makoto Chuma, Masatoshi Ishigami, Joseph K Hoang, Mayumi Maeda, Chung-Feng Huang, Adrian Gadano, Chia-Yen Dai, Jee-Fu Huang, Yasuhito Tanaka, Wan-Long Chuang, Seng Gee Lim, Ramsey Cheung, Ming-Lung Yu, Dae-Won Jun, Mindie H Nguyen 

    Link
  • 1

    Nomenclature dilemma of metabolic associated fatty liver disease (MAFLD): Considerable proportions of MAFLD are metabolic healthy

    Clinical Gastroenterology and Hepatology. 2022. Impact factor: 12.6

    Huiyul Park, Eileen L Yoon, Mimi Kim, Seon Cho, Eun-Hee Nah, Dae Won Jun

    Link